-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

Benzinga·07/06/2026 14:09:17
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $41 to $51.